Streetbeat News

Price Targets

VRCA

Needham analyst Serge Belanger has downgraded Verrica Pharmaceuticals from Buy to Hold, while maintaining a $12 price target.

Portfolio Pulse from Benzinga Newsdesk

October 03, 2024 | 9:33 am

STZ

Constellation Brands (NYSE:STZ) is set to release its Q2 earnings, with expectations of $4.08 EPS and $2.9 billion in revenue. The company revised its FY25 EPS forecast slightly upwards. Analysts have maintained positive ratings, with some adjusting price targets.

Portfolio Pulse from Avi Kapoor

October 03, 2024 | 8:44 am

ANGO

NKE

STZ

U.S. stocks closed slightly higher despite Middle East tensions, with the Fear & Greed Index in the 'Greed' zone. Nike shares fell 7% after price target cuts due to a revenue miss. Investors await earnings from Constellation Brands and AngioDynamics.

Portfolio Pulse from Avi Kapoor

October 03, 2024 | 7:27 am

TSLA

UBER

Tesla is set to host its Robotaxi event on October 10, where it may demonstrate its 'cybercab' and discuss its autonomous ride-sharing plans. Analyst Adam Jonas from Morgan Stanley has an Overweight rating and a $310 price target for Tesla, expecting a potential commercial launch in 2025 or 2026. Tesla may offer incentives to ride-share drivers and target high-density metro areas.

Portfolio Pulse from Shanthi Rexaline

October 03, 2024 | 6:32 am

HUM

B of A Securities has downgraded Humana from Neutral to Underperform and lowered its price target from $376 to $247.

Portfolio Pulse from Benzinga Newsdesk

October 02, 2024 | 10:03 pm

AVY

In the past three months, 8 analysts have provided ratings for Avery Dennison (NYSE:AVY), showing a range of sentiments from bullish to bearish. The average 12-month price target is $250.82, with a slight decrease in sentiment. Analysts have adjusted their ratings and price targets, reflecting their views on the company's market position and financial performance.

Portfolio Pulse from Benzinga Insights

October 02, 2024 | 9:02 pm

GS

Goldman Sachs Gr (NYSE:GS) has received varied analyst ratings over the past quarter, with a majority being somewhat bullish. The average 12-month price target has increased by 7.36% to $512.43. Analysts have raised their price targets, reflecting a positive outlook. Despite strong revenue growth and net margins, Goldman Sachs faces challenges with low ROE, ROA, and high debt-to-equity ratio.

Portfolio Pulse from Benzinga Insights

October 02, 2024 | 9:02 pm

PKG

Analysts have varied opinions on Packaging Corp of America (NYSE:PKG), with recent ratings showing a mix of bullish and indifferent sentiments. The average 12-month price target has increased by 5.3% to $208.5. Analysts have raised their price targets, reflecting positive sentiment despite some financial challenges.

Portfolio Pulse from Benzinga Insights

October 02, 2024 | 9:01 pm

TT

Trane Technologies (NYSE:TT) has been evaluated by 11 analysts over the past three months, with a mix of bullish and bearish sentiments. The average 12-month price target has increased to $363.55, with a high of $425.00 and a low of $310.00. Analysts have adjusted their ratings and price targets, reflecting their views on the company's market position and financial performance. Trane Technologies has shown a positive revenue trend with a 12.81% growth rate, though its net margin is below industry averages. The company's ROE and ROA are above industry standards, and it maintains a sound financial structure with a low debt-to-equity ratio.

Portfolio Pulse from Benzinga Insights

October 02, 2024 | 9:00 pm

AGL

Analysts have mixed ratings for Agilon Health (NYSE:AGL), with recent price targets ranging from $3.00 to $9.00. The average target has decreased by 9.88% to $6.2. Agilon Health shows strong revenue growth but struggles with profitability and returns.

Portfolio Pulse from Benzinga Insights

October 02, 2024 | 9:00 pm